Introduction
Prostaglandins (PGs) derived from arachidonic acid are a family of biologically active molecules having a diverse range of physiological functions. Some PGs have been reported to regulate growth, proliferation and differentiation of cells in response to a variety of stimuli (Smith, 1992; Chinery et al., 1999; Straus and Glass, 2001 ; Kondo et al., 2002) . Cyclopentenone prostaglandins (cyPGs), especially those of the A and J series, are characterized by the presence of a chemically reactive a,b-unsaturated carbonyl group. Because of the a,bunsaturated carbonyl group that constitutes the electrophilic carbon center, cyPGs are prone to undergo Michael addition reactions with various nucleophiles (Noyori and Suzuki, 1993) , such as the free sulfhydryl group of cysteine residues located in reduced glutathione (Cagen et al., 1975; Atsmon et al., 1990; Parker and Ankel, 1992; Gayarre et al., 2005) or many redoxregulated cellular proteins (Rossi et al., 2000; Straus et al., 2000; Cernuda-Morollon et al., 2001; Oliva et al., 2003; Perez-Sala et al., 2003; Shibata et al., 2003) . Of particular interest is 15-deoxy-D 12,14 -prostaglandin J 2 (15d-PGJ 2 ), one of the terminal products of the COX-2-mediated arachidonic acid pathway, that has been shown to covalently modify several transcription factors and other signaling molecules, including nuclear factorkB (Rossi et al., 2000; Straus et al., 2000; CernudaMorollon et al., 2001) , H-Ras (Oliva et al., 2003) , thioredoxin (Shibata et al., 2003) , AP-1 (Perez-Sala et al., 2003) , Keap1 (Levonen et al., 2004; Oh et al., 2008) , peroxisome proliferator-activated receptor-g (Shiraki et al., 2005) , eukaryotic initiation factor 4F (Kim et al., 2007b) and estrogen receptor-a (Kim et al., 2007a) .
The tumor suppressor protein p53 is a transcription factor regulating cell-cycle progression, cell survival and DNA repair in cells challenged with genotoxic stress. A complex and diverse set of posttranslational modifications, such as the site-specific phosphorylation, ubiquitination and sumoylation, governs the activity and stability of the p53 protein (Bode and Dong, 2004) . Phosphorylation and acetylation to achieve p53-mediated transcription of appropriate downstream targets have been well defined (Giaccia and Kastan, 1998) . Another potential posttranslational modification of p53 less extensively explored is redox regulation through oxidation/covalent modification of its cysteine thiols (Wu et al., 1999 (Wu et al., , 2000 Lambert et al., 2009) . Thus, target gene transactivation by p53 in human cells was found to be affected by oxidants and reducing agents (Verhaegh et al., 1997) , and the level of expression of reporter genes driven by a p53-responsive promoter was decreased by oxidant treatment (Merwin et al., 2002) . Furthermore, the transactivation of p53 is also sensitive to metal cations and Cu 2 þ /Cu þ redox cycling (Wu et al., 2000) .
The DNA-binding domain of human p53 contains 10 cysteine residues as potential targets for redox modification (Rainwater et al., 1995) . These cysteine thiol groups appear to be critical for binding of p53 to DNA that is influenced by thiol blocking agents (Hainaut and Milner, 1993; Rainwater et al., 1995) . Therefore, maintenance of proper redox status of the cysteine residues present in p53 is critical for regulating its DNAbinding and transcriptional activity (Delphin et al., 1994) . In addition, site-directed mutagenesis of certain cysteine residues of abrogated its binding to DNA (Chene, 1999; Buzek et al., 2002) , corroborating the essential function of the reduced state of cysteine thiols of p53 in exerting transcriptional activity. Analysis of the p53 crystal structure revealed several well-conserved cysteine residues (Cys124, 182, 229, 242 , and 277) exposed on the protein surface that may be susceptible to oxidation or modification by electrophiles (Wu et al., 1999) . Especially, Cys277 of p53 is essential for DNA binding and hence a principal target for redox regulation (Buzek et al., 2002) .
In this study, we explored the possibility that 15d-PGJ 2 , a representative electrophilic cyPG, could modify a critical cysteine residue of p53 especially Cys277, thereby affecting the DNA-binding and transcriptional activity of this tumor suppressor.
Results

15d
-PGJ 2 upregulates expression of p53 in MCF-7 cells 15d-PGJ 2 has been shown to induce apoptosis in human breast cancer cells (Clay et al., 2001; Pignatelli et al., 2005) but the involvement of p53 was not indicated. The MCF-7 breast carcinoma cell line expresses wild-type p53 and is commonly used as a cellular model in investigating p53 functions. We noted that treatment of MCF-7 cells with 15d-PGJ 2 (30 mM) resulted in the elevated p53 protein expression in a time-related manner ( Figure 1a ). Under the same experimental conditions, however, there was no concurrent increase in the p53 mRNA levels (Figure 1b) . Cycloheximide (CHX) abolished the enhancement of the p53 protein expression in a concentration-dependent manner (Figure 1c ), indicative of de novo protein synthesis required for the 15d-PGJ 2 -induced accumulation of the p53.
15d-PGJ 2 induces increased cytosolic and nuclear distribution of p53 in MCF-7 cells Several types of malignant and premalignant tissues harbor a genetically wild-type, but transcriptionally inactive form of p53, often localized in their cytoplasm (Levine et al., 1991; Moll et al., 1992 Moll et al., , 1995 Vogelstein and Kinzler, 1992; Agarwal et al., 1998) . As p53 is a transcription factor, its nuclear localization is essential for its activity (Kastan and Zambetti, 2003) .
We examined whether 15d-PGJ 2 could cause abnormal sequestration of p53 in the cytoplasm, thereby rendering this transcription factor inactive in its function. As shown in Figure 2 , levels of p53 protein increased in both cytosolic and nuclear fractions of MCF-7 cells treated with 15d-PGJ 2 as determined by western blot (Figure 2a ) and immunocytochemical ( Figure 2b ) analyses. Therefore, it is likely that 15d-PGJ 2 stabilizes p53 protein by blocking its degradation.
Treatment with 15d-PGJ 2 causes transcriptional inactivation of p53 Next, we determined whether increased p53 protein expression could lead to enhanced DNA binding in 15d-PGJ 2 -treated MCF-7 cells. Opposite to our initial expectation, however, the DNA-binding activity of p53 as assessed by electrophoretic mobility shift assay (EMSA) was gradually decreased in MCF-7 cells after treatment with 15d-PGJ 2 (Figure 3a) , suggesting that the accumulated p53 is unlikely to be functional. Further, the p53-DNA-binding activity was gradually decreased by treatment with 15d-PGJ 2 in p53-null PC-3 cells transiently transfected with a wild-type p53 expression vector (Figure 3b) . Moreover, p21 luciferase activity under the control of p53-responsive promoter was substantially reduced in 15d-PGJ 2 -treated MCF-7 cells, whereas the activity was enhanced by hydrogen peroxide used as a positive control (Figure 3c ). These 12,14 -prostaglandin J 2 (15d-PGJ 2 ) upregulates the expression of p53 protein in MCF-7 cells. MCF-7 cells were treated with 15d-PGJ 2 (30 mM) for indicated periods. Western blot analysis (a) and RT-PCR (b) were conducted to measure the levels of p53 protein and its mRNA transcript, respectively. Actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively, were measured for the confirmation of equal amounts of protein and mRNA loaded. (c) MCF-7 cells were exposed to 15d-PGJ 2 (30 mM) for 24 h in the absence or presence of cycloheximide (CHX; 0.4 or 4 mg/ml).
results suggest that 15d-PGJ 2 may impair the p53 function although it induces the cellular accumulation of this transcription factor.
An electrophilic carbon center of 15d-PGJ 2 is critical in affecting the stability of p53 Although 15d-PGJ 2 (Figure 4a , left) induced p53 protein expression in a concentration-related manner, MCF-7 cells treated with 9,10-dihydro-15d-PGJ 2 (Figure 4a , right) that lacks the electrophilic a,b-unsaturated moiety in the cyclopentenone ring failed to accumulate p53 protein (Figure 4b ). In addition, an immunostaining of MCF-7 cells with anti-p53 monoclonal antibody showed the p53 accumulation in both cytoplasm and nucleus in cells exposed to 15d-PGJ 2 , but not to the nonelectrophilic analog, H 2 -15d-PGJ 2 (Figure 4c ). These findings suggest that the a,b-unsaturated carbonyl group of 15d-PGJ 2 has a crucial function in stabilizing p53.
15d-PGJ 2 inhibits DNA-binding activity of p53 in vitro To determine whether 15d-PGJ 2 can directly interact with p53 protein, thereby inhibiting its DNA binding, we used nuclear extracts isolated from MCF-7 cells expressing intact wild-type p53. When nuclear extracts from unstimulated MCF-7 cells were mixed with 15d-PGJ 2 for 1 h at room temperature before EMSA, there was reduced DNA binding of p53 that was concentration dependent (Figure 5a ). In contrast, the same concentrations of H 2 -15d-PGJ 2 were much less inhibitory (Figure 5a ). In another experiment, recombinant human p53 protein was treated with 30 mM 15d-PGJ 2 or the same concentration of H 2 -15d-PGJ 2 for 1 h at room temperature and subjected to EMSA. As shown in the Figure 5b , 15d-PGJ 2 abrogated the p53 DNA binding, whereas H 2 -15d-PGJ 2 failed to. These results suggest that 15d-PGJ 2 interferes with the p53 DNA binding through direct modification of p53. To investigate the 
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Figure 2 15-Deoxy-D 12,14 -prostaglandin J 2 (15d-PGJ 2 ) induces increased cytosolic and nuclear distribution of p53 in MCF-7 cells. (a) MCF-7 cells were treated with 15d-PGJ 2 (30 mM) for indicated time periods, and both cytosolic (CE) and nuclear (NE) extracts were prepared and subjected to western blot analysis. Tubulin and lamin B1, respectively, were measured for the confirmation of equal amounts of cytosolic and nuclear fractions loaded. (b) Immunocytochemical analysis was performed using anti-p53 antibody after the treatment of MCF-7 cells with 15d-PGJ 2 (30 mM) for 0, 12, 24, 36 and 48 h. Cells were stained with propidium iodide (PI) and analyzed by confocal microscopy.
effect of cellular redox conditions on p53 conformation and DNA-binding activity, we exposed MCF-7 cells to the sulfhydryl reducing agent dithiothreitol (DTT). Preincubation of MCF-7 cells with DTT restored the p53 DNA-binding activity that was previously inhibited by 15d-PGJ 2 (Figure 5c ). These results imply that the inhibitory effect of 15d-PGJ 2 on p53-DNA binding may arise from its interaction with cysteine thiols of p53. To further verify that 15d-PGJ 2 could directly modify p53, we used a biotinylated derivative of 15d-PGJ 2 . Purified recombinant p53 was treated with biotinylated 15d-PGJ 2 (30 mM), and the complex was detected with horseradish peroxidase (HRP)-conjugated streptavidin. The amounts of biotinylated 15d-PGJ 2 directly bound to purified recombinant p53 were markedly reduced in the presence of excess 15d-PGJ 2 or DTT (Figure 5d ). To better clarify the involvement of the electrophilic carbon center of 15d-PGJ 2 in modification of p53, we transiently transfected p53-null PC-3 cells with an expression vector for wild-type p53. As shown in Figure 5e , wild-type p53 expressing PC-3 cells elicited p53 bound to biotinylated 15d-PGJ 2 . Again, the biotinylated H 2 -15d-PGJ 2 failed to interact with p53 ( Figure 5e ). Furthermore, biotinylated 15d-PGJ 2 (30 mM) was treated to MCF-7 cells expressing the wild-type p53, and then immunocytochemical analyses were performed with antibodies against p53 and tetramethylrhodamine-conjugated streptavidin. The accumulation of the p53 bound to biotinylated 15d-PGJ 2 was visualized with tetramethylrhodamine-conjugated streptavidin (Figure 5f ).
A putative target for covalent modification of p53 by 15d-PGJ 2 is cysteine 277 As mentioned earlier, the redox state of p53 influences its specific DNA binding. Reduction of p53 cysteines leads to its enhanced binding, whereas oxidation abolishes it. The DNA-binding domain of human p53 contains 10 cysteine residues, which are vulnerable to oxidation (Hainaut and Milner, 1993) . Among these, cysteine 277 is considered to be a plausible site for covalent modification or oxidation because of its proximity to the protein surface (Cho et al., 1994; Buzek et al., 2002) . To verify this hypothesis, we transiently transfected p53-null PC-3 cells with a mutant p53 construct in which cysteine 277 was replaced by alanine (C277A). PC-3 cells expressing wild-type p53 exhibited marked binding to biotinylated 15d-PGJ 2 , but those harboring mutation at cysteine 277 did not ( Figure 6a ). Site-directed mutation of another redoxsensitive cysteine (Cys124) barely affected the p53 binding to 15d-PGJ 2 . These results clearly indicate that the cysteine 277 residue of p53 represents a critical target for covalent modification by 15d-PGJ 2 in intact cells. To further corroborate that cysteine 277 is essential for p53 modification by 15d-PGJ 2 , we conducted the gel shift assay using [ 35 S]-labeled translated p53. The DNA-binding activity of p53 was reduced in 15d-PGJ 2 -treated wild-type lysates but p53 mutant lysates in which cysteine 277 was replaced by alanine were virtually unaffected by treatment with 15d-PGJ 2 ( Figure 6b ).
Redox modification of p53 by 15d-PGJ 2 may induce conformational changes that would affect its protein stability To determine whether covalent modification of p53 could affect its degradation in 15d-PGJ 2 -treated MCF-7 cells, we incubated cells in the presence or absence of 15d-PGJ 2 (30 mM) and treated them with the protein synthesis inhibitor CHX (10 mg/ml). MCF-7 cells treated with 15d-PGJ 2 exhibited the prolonged half-life of p53 protein ( Figure 7a ). Moreover, 15d-PGJ 2 were treated for 12 h to PC-3 cells transiently expressing wild-type MCF-7 cell lysate -
12,14 -prostaglandin J 2 (15d-PGJ 2 ) inhibits DNA-binding capability of p53 through interaction of p53. (a) Nuclear extracts isolated from MCF-7 cells were incubated in vitro in the presence of 15d-PGJ 2 (10 or 30 mM) or H 2 -15d-PGJ 2 (30 mM) for 1 h at room temperature, after which the p53 DNA-binding activity was analyzed by electrophoretic mobility shift assay (EMSA). (b) Recombinant human p53 protein was treated with 15d-PGJ 2 (10 or 30 mM) or H 2 -15d-PGJ 2 (30 mM) for 1 h at room temperature and subjected to EMSA. (c) MCF-7 cells were pretreated with the reducing agent dithiothreitol (DTT; 1 mM) for 2 h before treatment with 15d-PGJ 2 . The p53 DNA-binding activity was determined by EMSA at 36 h. (d) Purified recombinant p53 was incubated with biotinylated 15d-PGJ 2 , and the resulting adduct with horseradish peroxidase (HRP)-streptavidin, in the presence or absence of excess 15d-PGJ 2 (1 mM) or DTT (2 mM). Incubation mixtures were subjected to SDS-PAGE and western blot analysis followed by detection with HRP-streptavidin or anti-p53 antibody. (e) p53-null PC-3 cells transiently were transfected with a pcDNA (MOCK) or wild-type p53 (WT p53) expression vector. PC-3 cells were treated with 30 mM biotinylated 15d-PGJ 2 or the same concentration of biotinylated H 2 -15d-PGJ 2 for 6 h. p53 was immunoprecipitated with p53 antibody and analyzed by western blot analysis followed by detection with HRP-conjugated streptavidin. (f) MCF-7 cells treated with 30 mM biotinylated 15d-PGJ 2 or the same concentration of biotinylated H 2 -15d-PGJ 2 for 24 h, and then subjected to immunocytochemical analysis with primary antibody against p53. Biotinylated chemicals were visualized with tetramethylrhodamine (TMR)-conjugated streptavidin. p53 or mutant C277A p53. Then, these cells were incubated with CHX for indicated time. Stability of p53 protein was increased by treatment with 15d-PGJ 2 in the PC-3 cells expressing wild-type p53 compared with cells harboring mutated cysteine 277 (Figure 7b ). These findings suggest that modification of p53 by 15d-PGJ 2 may cause a conformational change, which renders p53 less susceptible to proteasomal degradation after ubiquitination. In another experiment, 15d-PGJ 2 -treated MCF-7 cells were lysed using buffer including N-ethylmaleimide. p53 was then immunoprecipitated with anti-p53, fractionated by SDS-polyacrylamide gel (PAGE) and subjected to immunoblot analysis with an antibody against ubiquitin. As shown in Figure 7c , ubiquitinated p53 was accumulated in a time-related manner in MCF-7 cells treated with 15d-PGJ 2 . MDM2 has the capability of catalyzing both monoubiquitination and polyubiquitination of p53, and the differential profiles of p53 ubiquitination were attained, depending on the levels of MDM2 (Li et al., 2003) . Ubiquitinated-p53 accumulated in MCF-7 cells treated with 15d-PGJ 2 is supposed to be the monoubiquitinated p53 based on the band pattern ( Figure 7c and also Supplementary Figure 1) . Recently, Brooks et al. (2007) have reported that monoubiquitination of p53 impairs its site-specific DNA binding.
Stability of p53 is regulated by MDM2 and NQO1
As shown in Figure 1 , MCF-7 cells express a detectable basal level of p53 protein that is increased gradually after treatment with 15d-PGJ 2 , but upregulation of p53 Barak et al., 1993; Wu et al., 1993) . The basal level of MDM2 protein was low in MCF-7 cells, but transiently increased 6-12 h after treatment with 15d-PGJ 2 and then decreased back to near basal levels by 24 h (Figure 8a ). 
Covalent modification of p53 cysteine thiol D-H Kim et al
In contrast to p53, the increase in MDM2 protein level after 15d-PGJ 2 was accompanied by an elevated level of its mRNA transcript (Figure 8b) . At 12 h after treatment with 15d-PGJ 2 , the expression of MDM2 protein was prominent in the nuclei of all cells examined. By 24 h, the intensity of MDM2 staining in the nuclei of most cells was decreased (Figure 8c ), in agreement with the results obtained by western blotting. These findings suggest that transient MDM2 expression in MCF-7 cells treated with 15d-PGJ 2 accounts for the downregulation of p53 transcriptional activity as well as accumulation of monoubiquitinated p53. In addition, we noted that the stability of cytoplasmic p53 in MCF-7 cells treated with 15d-PGJ 2 is regulated by NAD(P)H:quinone oxidoreductase (NQO1). Thus, pretreatment of dicoumarol, an inhibitor of NQO1 activity that competes with NAD(P)H for binding to NQO1 (Hosoda et al., 1974) , attenuated the stability of p53 induced by 15d-PGJ 2 in MCF-7 cells (Figure 8d ). Therefore, 15d-PGJ 2 -induced p53 accumulation in both cytosol and nucleus is likely to be regulated by both MDM2 and NQO1 like the two cogwheels.
Discussion
Inappropriately elevated COX-2 upregulation could contribute to promotion of cell proliferation, metastasis and angiogenesis, and resistance to apoptosis (Tsujii et al., 1998; Fischer, 2002; Muller-Decker et al., 2002; Tiano et al., 2002; Furstenberger et al., 2003) . One of the terminal products of the COX-2-mediated arachidonic acid pathway is 15d-PGJ 2 , which is formed by dehydration and isomerization of PGD 2 . The generation of 15d-PGJ 2 has been reported to increase under inflammatory conditions associated with COX-2 induction (Gilroy et al., 1999 2008). Thus, 15d-PGJ 2 potentiates mouse skin tumor formation (Millan et al., 2006) , accelerates the proliferation of leukemia cells (Azuma et al., 2004) and colorectal cancer cells (Chinery et al., 1999) and has a capability to induce angiogenesis (Chinery et al., 1999; Azuma et al., 2004) . Correlation between COX-2 expression and p53 accumulation has been suggested in human cancer tissues (Biramijamal et al., 2001; Leung et al., 2001; Shigemasa et al., 2003) . Notably, p53 protein levels increased during the progression of papillomas formed in mouse skin topically applied with 15d-PGJ 2 (Millan et al., 2006) , indicative of the interplay between p53 and COX-2 (Han et al., 2002) . Consistent with this report, our data reveal that 15d-PGJ 2 treatment results in the p53 protein accumulation in human breast cancer (MCF-7) cells. Several studies have identified complex crosstalks between p53 and COX-2, whereby p53 can either up-or downregulate COX-2, which in turn controls p53 transcriptional activity (de Moraes et al., 2007) . However, the molecular basis of such p53-COX-2 axis is open to debate.
Previous reports suggest that PGs not only participate in initiation, but may also actively contribute to the resolution of inflammation. In addition, the so-called nonsteroidal anti-inflammatory drugs, by inhibiting PG production, may actually have mixed anti-inflammatory and pro-inflammatory effects (Scher and Pillinger, 2009 ). Indeed, in animal models, administration of an 12,14 -prostaglandin J 2 (15d-PGJ 2 ) may induce conformational changes that would affect its protein stability. (a) MCF-7 cells were incubated in the presence or absence of 15d-PGJ 2 (30 mM) for 24 h and then cells were treated with cycloheximide (CHX; 10 mg/ml). Cell extracts were harvested at the indicated times and subjected to western blot analysis. (b) p53-null PC-3 cells were transiently transfected with wild-type p53 (WT p53) or Cys277Ala p53 (C277A p53) expression vectors, and then treated with 15d-PGJ 2 for 2 h. CHX (20 mg/ml) was added and cell extracts were harvested at the indicated times. Western blot analysis was conducted to measure the levels of p53 protein. (c) MCF-7 cells were treated with 15d-PGJ 2 (30 mM) for indicated time periods, and p53 was immunoprecipitated with anti-p53, fractionated by SDS-PAGE, and subjected to immunoblot analysis with an antibody against ubiquitin. nonsteroidal anti-inflammatory drug early in the course of inflammation seems to abrogate inflammation, whereas administration of the same drug after the onset of inflammation resolution may actually prolong the inflammatory response (Gilroy et al., 1999; Rajakariar et al., 2007) . 15d-PGJ 2 is considered as a double-edged sword in the context of its pro-and anti-inflammatory functions (Kim and Surh, 2008) . Moreover, this cyPG stimulates cell proliferation at relatively lower concentrations whereas it induces apoptosis at the higher concentrations (Levonen et al., 2001; Bureau et al., 2002; Emi and Maeyama, 2004) . Thus, 15d-PGJ 2 has differential effects on the survival or apoptosis of human umbilical vein endothelial cells. Low concentrations are cytoprotective by a mechanism that involves an increase in intracellular glutathione, whereas higher concentrations are cytotoxic (Levonen et al., 2001) . Such dual effects of 15d-PGJ 2 may depend on cell types as well as concentrations of 15d-PGJ 2 and duration of exposure to it.
The physiological significance of p53 accumulation in MCF-7 cells treated with 15d-PGJ 2 is of particular interest. Pignatelli et al. (2005) have reported that 15d-PGJ 2 triggers MCF-7 breast cancer cell death mainly by inducing early mitochondrial alterations, but some cells eventually restore the mitochondrial transmembrane potential, indicating heterogeneity of these cells. In addition, 15d-PGJ 2 induced COX-2 upregulation that -prostaglandin J 2 (15d-PGJ 2 ) (30 mM) for indicated periods. Western blot analysis (a) and RT-PCR (b) were conducted to measure the levels of MDM2 protein and its mRNA transcript, respectively. Actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively, were measured for the confirmation of equal amounts of protein and mRNA loaded. (c) Immunocytochemical analysis was performed using anti-MDM2 antibody after the treatment of MCF-7 cells with 15d-PGJ 2 (30 mM) for 0, 6, 12, 24 and 36 h. Cells were stained with propidium iodide (PI) and analyzed by confocal microscopy. (d) MCF-7 cells were exposed to dicoumarol (100 or 250 mM) for 2 h before 15d-PGJ 2 (30 mM) for 24 h. might be associated with its oncogenic potential in MCF-7 cells . In another study, 15d-PGJ 2 was found to upregulate vascular endothelial growth factor expression by induction of heme oxygenase-1 (HO-1) in MCF-7 cells that may contribute to increased angiogenic potential . Although 15d-PGJ 2 accumulates p53 protein, it induces inactivation of the function of p53 as evidenced by reduced p53 DNAbinding activity and p21 luciferase activity containing p53-responsive promoter in MCF-7 cells.
15d-PGJ 2 has an a,b-unsaturated carbonyl group containing two potentially reactive electrophilic carbon centers, one in the cyclopentenone ring moiety and the other in a side chain (Straus and Glass, 2001; Na and Surh, 2003; Levonen et al., 2004) . There are several reports suggesting that 15d-PGJ 2 can directly react with sulfhydryl groups of cysteine residues present in some critical cellular proteins by Michael addition, resulting in substantial alterations in their functions (Rossi et al., 2000; Straus et al., 2000; Cernuda-Morollon et al., 2001; Oliva et al., 2003; Perez-Sala et al., 2003; Shibata et al., 2003) . 9,10-Dihydro-15d-PGJ 2 , which differs from 15d-PGJ 2 only in the absence of the endocyclic double bond, was unable to inhibit p53 DNA-binding activity as well as to induce p53 expression, lending support that the electrophilic carbon center at position 9 of 15d-PGJ 2 is critical for modification and stabilization of p53 by this cyPG. These findings prompted us to determine whether 15d-PGJ 2 could directly inactivate the wild-type p53 tumor suppressor protein. Moos et al. (2000) have reported that PGA 1 and PGA 2 , by acting as electrophiles, alter the conformation of wild-type p53 in RKO and HCT116 colon cancer cells, cause cellular accumulation of p53 and disturb the transcriptional function and spatial distribution of p53. Mullally et al. (2001) have also reported that electrophilic eicosanoids of the J series can inactivate genetically wild-type tumor suppressor p53. A recent work by Pande and Ramos (2005) further supports the possibility of p53 being a target for direct modification. In agreement with this report, our study reveals that 15d-PGJ 2 can directly modify p53 as assessed by use of biotinylated 15d-PGJ 2 . This, in turn, abrogates p53 DNA-binding activity, leading to functional inactivation of this tumor suppressor. Although 15d-PGJ 2 stabilizes the p53 protein in MCF-7 cells, its DNA-binding and transcriptional activities appear to be lost through thiol modification.
The DNA-binding domain of human p53 contains 10 cysteine residues as potential targets for redox modification that may influence its DNA binding (Rainwater et al., 1995) . Cysteine residues (Cys124, 176, 182, 242, and 277) of human p53 are prone to be oxidized because of their proximity to the protein surface (Cho et al., 1994; Buzek et al., 2002) . Our site-directed mutagenesis experiment provides direct evidence that 15d-PGJ 2 can cause the modification of cysteine 277 in the human p53 protein. There are some reports in regard to the possibility of p53 stability by affecting on the conformation changes through redox modification (Velu et al., 2007; Liu et al., 2008) . It is noticeable that there is cellular accumulation of oxidized p53 (Wu et al., 2000; Seemann and Hainaut, 2005) . In accordance with these findings, redox modification of p53 by 15d-PGJ 2 is likely to elevate the p53 protein stability through its conformational change, which renders p53 less susceptible to proteasomal degradation. Furthermore, recently, Lambert et al. (2009) have shown that PRIMA-1 and its methylated analog form covalent adducts with thiols in mutant p53 and restore their tumor suppressor activity.
An intriguing question is how p53 that accumulates after treatment with 15d-PGJ 2 can retain sustained stability without exerting transcriptional and DNAbinding activity. It is widely accepted that MDM2 is a key mediator of p53 degradation/ubiquitination and that the endogenous levels of MDM2 are dynamically regulated via the p53-MDM2 feedback loop (Lev Bar-Or et al., 2000; Vogelstein et al., 2000) . Low levels of MDM2 activity induce monoubiquitination and nuclear export of p53, whereas high levels promote polyubiquitination and degradation of p53 (Li et al., 2003) . Recently, it has been reported that monoubiquitinated p53 retains its ability to tetramerize but loses the transcriptional activity. The loss of transcriptional activity is attributed to the inability of p53 to bind DNA and activate target promoters (Brooks et al., 2007) . In our present study, accumulation of monoubiquitinated p53 by 15d-PGJ 2 appears to contribute to the inactivation of DNA-binding and transcriptional activity. NQO1 also regulates p53 stability through ubiquitin-independent 20S proteasomal degradation (Asher and Shaul, 2006) . We observed that inhibition of NQO1 activity attenuated the stability of p53 induced by 15d-PGJ 2 in MCF-7 cells. Accordingly, stability of exported cytoplasmic p53 by 15d-PGJ 2 in MCF-7 cells seems to be regulated by NQO1 activity. Taken together, these observations suggest that stability of p53 by 15d-PGJ 2 appears to be regulated by expression and/or activity of MDM2 and NQO1.
In conclusion, 15d-PGJ 2 that has an electrophilic carbon centers directly interacts with p53, presumably at a cysteine 277 residue through nucleophilic addition. This, in turn, abrogates p53 DNA binding, leading to functional inactivation of this tumor suppressor. Moreover, modification of p53 by 15d-PGJ 2 may cause a conformational change, which renders p53 less susceptible to proteasomal degradation ( Figure 9 ). All of these findings suggest that the high levels of 15d-PGJ 2 as a consequence of increased COX-2 expression trigger modification of cysteine residue of p53, leading to stabilization of structurally modified p53 and subsequently its functional inactivation, which may contribute to the carcinogenesis.
Materials and methods
Reagents 15d-PGJ 2 and 9,10-dihydro-15d-PGJ 2 were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). Biotinylated 15d-PGJ 2 was kindly provided by Dr Y-G Suh (Seoul National University, Seoul, Korea). RPMI 1640 medium, F-12 Nutrient medium and fetal bovine serum were purchased from Gibco-BRL (Grand Island, NY, USA). Antibodies against p53 and actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Sigma-Aldrich (St Louis, MO, USA). The anti-rabbit and anti-mouse HRP-conjugated secondary antibodies were purchased from Zymed Laboratories (San Francisco, CA, USA). Recombinant p53 protein was supplied from Active Motif (Carlsbad, CA, USA). Oligonucleotide probes containing p53 consensus sequences were obtained from Santa Cruz Biotechnology. The enhanced chemiluminescence and [g-32 P]ATP were supplied from Amersham Pharmacia Biotech (Buckinghamshire, UK). The tetramethylrhodamine conjugate-streptavidin was purchased from Molecular Probes (Invitrogen, Carlsbad, CA, USA).
Cell culture MCF-7 cells were maintained routinely in RPMI 1640 medium supplemented with 10% fetal bovine serum and a 100 ng/ml penicillin/streptomycin/fungizone mixture at 37 1C in a humidified atmosphere of 5% CO 2 /95% air. PC-3 cells were grown in F-12 Nutrient medium plus 10% fetal bovine serum and antibiotics. The cells were plated at an appropriate density according to each experimental scale.
Plasmid constructions of p53 pcDNA3.1-v5-HisA-p53 was generated by PCR using the pcDNA-3.1 expression vector and wild-type p53 cDNA as template. PCR fragments were purified, cloned into the XbaI sites of pcDNA3.1-v5-HisA (Invitrogen). Mutations in wild-type p53 were introduced by site-directed mutagenesis using a Quick Site-Directed Mutagenesis kit (Stratagene, Cedar Creek, TX, USA) according to the manufacturer's protocol. The following complementary primer pairs were used: Cys124Ser: sense, 5 0 -GCCAAGTCTGTGACTAGCACGTACTCCCCTG CC-3 0 ; antisense, 5 0 -GGCAGGGGAGTACGTGCTAGTCA CAGACTTGGC-3 0 ; Cys277Ala: sense, 5 0 -GTGCGTGTT TGTGCCGCTCCTGGGAGAGACCGG-3 0 ; antisense, 5 0 -CC GGTCTCTCCCAGGAGCGGCACAAACACGCAC-3 0 . The DNA sequences of all plasmids were verified by sequencing (Big Dye terminator and ABI/HITACIHI 3730xl Genetic Analyzer; Bionics Co., Seoul, Korea).
Transient transfection PC-3 cells were plated at a confluence of 60% in 100 mm dish and grown in F12-Nutrient medium supplemented with 10% heat-inactivated fetal bovine serum at 37 1C in a humidified atmosphere of 5% CO 2 /95% air. Transient transfections were performed using the FuGene 6 transfection reagents according to the instructions supplied by the manufacturer (Roche Applied Science, Mannheim, Germany). After 48 h transfection, cells were treated with 15d-PGJ 2 or biotinylated 15d-PGJ 2 , and the cell lysis was performed with indicated lysis buffer.
Western blot analysis MCF-7 cells were lysed in RIPA lysis buffer (150 mM NaCl, 0.5% Triton Â 100, 50 mM Tris-HCl (pH 7.4), 25 mM NaF, 20 mM EGTA, 1 mM DTT, 1 mM Na 3 VO 4 , protease inhibitor cocktail tablets) for 15 min on ice followed by centrifugation at 12 000 g for 20 min. The protein concentration of the supernatant was measured by using the BCA reagents (Pierce, Rockford, IL, USA). Protein (30 mg) was separated by running Figure 9 A proposed mechanism underlying 15-deoxy-D 12,14 -prostaglandin J 2 (15d-PGJ 2 )-induced p53 cysteine modification. 15d-PGJ 2 has an electrophilic carbon center and can easily undergo nucleophilic addition to p53, presumably at cysteine 277 residue. This, in turn, abrogates DNA binding of p53, leading to functional inactivation of this tumor suppressor. Moreover, the covalent modification of p53 by 15d-PGJ 2 may cause a conformation change, which renders p53 less susceptible to proteasomal degradation. through 8-10% SDS-PAGE gel and transferred to the PVDF membrane (Gelman Laboratory, Ann Arbor, MI, USA). The blots were blocked with 5% nonfat dry milk/PBST buffer (phosphate-buffered saline (PBS) containing 0.1% for 1 h at room temperature. The membranes were incubated for 4 h at room temperature with 1:1000 dilution of one of the monoclonal antibody of p53 (Santa Cruz Biotechnology) and MDM2 (Calbiochem, Darmstadt, Germany) . Equal lane loading was assessed using Actin (Sigma-Aldrich). The blots were rinsed three times with PBST buffer for 5 min each. Washed blots were incubated with 1:5000 dilution of the HRPconjugated secondary antibody (Zymed Laboratories) for 1 h and washed again three times with PBST buffer. The transferred proteins were visualized with an enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech).
Preparation of cytosolic and nuclear proteins Confluent cells in 100 mm dishes were treated with 15d-PGJ 2 . Cells were gently washed twice with ice-cold PBS, scraped in 1 ml PBS and centrifuged at 12 000 g for 30 s at 4 1C. Pellets were suspended in 400 ml of hypotonic buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 2 mM MgCl 2 , 1mM DTT, 0.1 mM EDTA and 0.1 mM phenylmethylsulfonyl fluoride (PMSF)) for 15 min on ice, and 4 ml of 10% Nonidet P-40 solution was added for 5 min. The mixture was then centrifuged for 6 min at 12 000 g, washed once with 400 ml of PBS and suspended in 100 ml of buffer C (50 mM HEPES (pH 7.9), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 mM PMSF and 10% glycerol) for 20 min on ice and centrifuged for 6 min at 12 000 g. The supernatant containing nuclear proteins was collected and stored at À70 1C after determination of the protein concentration.
Electrophoretic mobility shift assay EMSA was performed using a DNA/protein binding detection kit according to the manufacturer's protocol (Gibco-BRL). Briefly, the p53 oligonucleotide probe (5 0 -TACAGAA-CATGTCTAAGCATGCTGGGGACT-3 0 ) was labeled with [g-32 P]ATP using T4 polynucleotide kinase and separated from unincorporated [g-32 P]ATP by gel filtration using a nick spin column (Amersham Biosciences). Before addition of the 32 Poligonucletide (100 000 c.p.m.), 10 mg of nuclear extract was kept on ice for 15 min in gel shift binding buffer (10 mM TrisHCl (pH 7.5), 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 4% (v/v) glycerol and 0.1 mg/ml sonicated salmon sperm DNA). To determine the sequence specificity of the p53 DNA interaction, we added the excess amount of unlabeled oligonucleotides. After 20-min incubation at room temperature, 2 ml of 0.1% bromophenol blue was added, and samples were electrophoresed through 6% nondenaturing PAGE at 150 V in a cold room. Finally, the gel was dried and exposed to an X-ray film.
Immunocytochemical analysis of p53
To determine the p53 localization, we adopted the immunocytochemical method that used a monoclonal antibody recognizing p53. Cells (1 Â 10 5 cells per 600 ml in four-well chamber slides) were fixed in 95% methanol/5% acetic acid solution for 10 min at À20 1C. After a rinse with PBS, cells were blocked for 1 h at room temperature in fresh blocking buffer (0.5% Tween-20 in PBS (pH 7.4), containing 10% normal goat serum). Dilutions (1:100) of primary anti-p53 antibody were made in PBS with 1% bovine serum albumin, and cells were incubated overnight at 4 1C. After three washes with PBST (PBS containing 0.1% Tween-20), the cells were incubated FITC-goat anti-mouse IgG secondary antibody in PBST with 3% bovine serum albumin for 1 h at room temperature. Cells were rinsed with PBS, and stained cells were analyzed under a confocal microscope and photographed.
In vitro expression of wild-type and mutant p53 p53 proteins (wild-type and mutants) were expressed in vitro transcribed/translated, using the TNT reticulocyte lysate system kit (Promega, Madison, WI, USA) in the presence of [ 35 S]methionine to label the proteins. Synthetic proteins were then analyzed by SDS-PAGE, electrophoresis and autoradiography.
In vitro p53 DNA-binding assay Aliquots (10 ml) of translated lysate treated with 15d-PGJ 2 were diluted in 50 ml of DNA-binding buffer (20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.1% Nonidet P-40 and 10% glycerol), containing 5 ng of 32 P end-labeled p53 double stranded oligonucleotide, 1 mg of salmon-stranded DNA as a nonspecific competitor, DTT (5 mM) and 100 ng of Pab421 antibody. The Pab421 is required to detect DNA binding of wild-type p53 translated in vitro (Hainaut and Milner, 1993; Calmels et al., 1997) . For analysis of p53 DNAbinding activity in response to changes in the redox potential using recombinant human p53 protein, we followed methods of Klatt and Lamas (2002) . To stabilize p53 in solution, we performed incubations in a 20 mM Tris-HCl buffer (pH 7.5) containing 50 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, 5% (v/v) glycerol and 0.01% (v/v) Nonidet P-40. Purified recombinant p53 protein at final concentration of 10 mM incubated with 15d-PGJ 2 or H 2 -15d-PGJ 2 in a test tube. After incubation at room temperature for 1 h, samples are immediately processed for DNA-binding assays as follows. For the determination of DNA-binding activity, preincubation mixture are added 0.2 mg/ml bovine serum albumin, 0.1 mg/ml poly(dI-dC) and a 32 P-labeled double-stranded oligonucleotide, which contains a p53 DNA-binding consensus sequence. Subsequently, samples are cooled to room temperature and subjected to EMSA.
Reaction of p53 with biotinylated 15d-PGJ 2 Recombinant p53 protein at 50 nM in 20 mM Tris-HCl (pH 8.0), 100 mM KCl, 1 mM DTT, 0.2 mM EDTA and 20% glycerol was incubated for 2 h at room temperature in the presence of vehicle (DMSO) or 30 mM biotinylated 15d-PGJ 2 in a final volume of 50 ml. Incorporation of biotin was assessed by western blot and detection with HRP-conjugated streptavidin and enhanced chemiluminescence (Amersham Pharmacia Biotech).
Binding of biotinylated 15d-PGJ 2 to p53 in intact cells PC-3 cells transiently transfected with p53 plasmids were incubated with biotinylated 15d-PGJ 2 for 12 h. Cells were lysed in 250 mM sucrose, 50 mM Tris-HCl (pH 8.0), 25 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 2 mM NaF, 2 mM sodium orthovanadate and 1 mM PMSF. Cell lysates were immunoprecipitated with p53 antibodies, and the incorporation of biotinylated 15d-PGJ 2 into immunoprecipitated protein was monitored by western blot analysis and detection with HRP-conjugated streptavidin antibody (Pierce).
Immunoprecipitation
The binding of biotinylated-15d-PGJ 2 or biotinylated-9,10-dihydro-15d-PGJ 2 and p53 was examined by immunoprecipitation assay. The whole-cell lysate prepared from MCF-7 cells was used to measure the activity according to the protocol described by Kundu et al. 2006) . Briefly, cellular proteins (500 mg) were subjected to immunoprecipitation by shaking with p53 (Santa Cruz Biotechnology) primary antibody at 4 1C for 12 h followed by the addition of protein G-agarose bead suspension (25% slurry, 40 ml) and additional shaking for 2 h at the same condition. After centrifugation at 10 000 g for 1 min, immunoprecipitated beads were collected by discarding the supernatant and washing with cell lysis buffer. After final washing, immunoprecipitate was resuspended in 40 ml of 2 Â SDS electrophoresis sample buffer and boiled for 5 min. Supernatant (30 ml) from each sample was collected after centrifugation and loaded on SDS-PAGE.
Luciferase reporter gene assay p21 luciferase vector containing the p53-responsive promoter was kindly provided by Dr Yi Sun (Michigan University, USA). MCF-7 cells were plated at a confluence of 60% in sixwell plate and grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum at 37 1C in a humidified atmosphere of 5% CO 2 /95% air. Transient transfections were performed using the FuGene 6 transfection reagents according to the instructions supplied by the manufacturer (Roche Applied Science). After 48 h transfection, cells were treated with 15d-PGJ 2 for additional 12 h, and the cell lysis was performed with the reporter lysis buffer. After mixing the cell extract with a luciferase substrate (Promega), the luciferase activity was measured by the luminometer (AntoLumat LB953; EG&G Berthold, Bad Wildbad, Germany). The bgalactosidase assay was performed according to the supplier's instructions (Promega b-Galactosidase Enzyme Assay System) for normalizing the luciferase activity. were resolved by 1-1.5% agarose gel electrophoresis, stained with ethidium bromide and photographed under ultraviolet light.
Measurement of half-life of p53
For measurement of p53 stability, MCF-7 cells were seeded into 60 mm dish and allowed to grow for 36 h (about 70-80% confluency), and then cells were incubated with either vehicle or 15d-PGJ 2 for 24 h. Then the media were replaced with media containing cycloheximide (10 mg/ml; Sigma-Aldrich), a protein synthesis inhibitor, and cells were harvested at various time periods. A day before transfection, PC-3 cells (1 Â 10 5 per ml) were seeded into 60 mm dish. Cells were transfected with each 2 mg of wild-type or mutant p53 with FuGene 6 transfection reagents. After 36 h, cells were treated with 15d-PGJ 2 for 12 h, and then cells were treated with cycloheximide (20 mg/ml). Cell lysates were subjected to western blot analysis with p53-specific DO-1 antibody.
Analysis of p53 ubiquitination
Cells were scraped and lysed in 250 mM sucrose, 50 mM Tris-HCl (pH 8.0), 25 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 10 mM N-ethylmaleimide, 2 mM NaF, 2 mM sodium orthovanadate and 1 mM PMSF. p53 was immunoprecipitated using a rabbit polyclonal p53 antibody (FL393; Santa Cruz Biotechnology) as described above. Beads were washed three times with lysis buffer. After resolving the samples by SDS-PAGE, membranes were probed with mouse monoclonal antibody to ubiquitin (Calbiochem).
Statistical analysis
When necessary, data were expressed as means±s.d. of at least three independent experiments, and statistical analysis for single comparison was performed using the Student's t-test. The criterion for statistical significance was Po0.05.
